Louie Mar Gangcuangco
Public Health & General Preventive Medicine · Honolulu, HINPI 1891100319
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,643 of the $20,224 with a category attached, or 62.5%. Gilead accounts for 80.0% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $17,441, more than ten times the $305 reported in 2022.
Across 143 payments — averaging $141.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$16K
- Viiv Healthcare Company$1K
- Otsuka America Pharmaceutical, Inc.$585
- AbbVie$416
- Otsuka Pharmaceutical Development & Commercialization, Inc.$292
- Merck$287
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$12,64363%
- Travel & lodging$1,1766%
- Food & beverage$6,40532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 52 | $16,171 |
| Viiv Healthcare Company | 25 | $1,454 |
| Otsuka America Pharmaceutical, Inc. | 18 | $585 |
| AbbVie | 13 | $416 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $292 |
| Merck | 11 | $287 |
| EMD Serono, Inc. | 3 | $180 |
| Novo Nordisk | 2 | $142 |
| Abbott | 1 | $125 |
| Alkermes, Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $116 |
| Madrigal Pharmaceuticals | 3 | $113 |
| Boehringer Ingelheim | 3 | $81 |
| Johnson & Johnson | 2 | $39 |
| GSK | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few public health & general preventive medicine providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 21 | $88,080 |
| DovatoDolutegravir Sodium/Lamivudine | 21 | $71,696 |
| Amlodipine Besylate | 20 | $170 |
| Atorvastatin Calcium | 11 | $128 |
| Lisinopril | 18 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $16,171 | $88,08021 claims |
| Viiv Healthcare CompanyDovato | $1,454 | $71,69621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few public health & general preventive medicine providers in Hawaiion file to place this against a meaningful peer group, so we don't.
Other public health & general preventive medicine in Honolulu
- Leanna GordonHonolulu$506
- Ed FessHonolulu$50
- Arthur BrownsteinHonolulu$20
- Terry ShintaniHonolulu$15
- Anastasia MaletzCamp Smith$131
- Frederick LandroJbphh$115
- Matthew JustusPearl Harbor$55
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.